PMID- 28184163
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20220317
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 12
DP  - 2017
TI  - Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: 
      pharmacokinetics and biodistribution profile.
PG  - 935-947
LID - 10.2147/IJN.S121881 [doi]
AB  - Docetaxel is a highly potent anticancer agent being used in a wide spectrum of 
      cancer types. There are important matters of concern regarding the drug's 
      pharmacokinetics related to the conventional formulation. 
      Poly(lactide-co-glycolide) (PLGA) is a biocompatible/biodegradable polymer with 
      variable physicochemical characteristics, and its application in human has been 
      approved by the United States Food and Drug Administration. PLGA gives polymeric 
      nanoparticles with unique drug delivery characteristics. The application of PLGA 
      nanoparticles (NPs) as intravenous (IV) sustained-release delivery vehicles for 
      docetaxel can favorably modify pharmacokinetics, biofate, and pharmacotherapy of 
      the drug in cancer patients. Surface modification of PLGA NPs with poly(ethylene 
      glycol) (PEG) can further enhance NPs' long-circulating properties. Herein, an 
      optimized fabrication approach has been used for the preparation of PLGA and 
      PLGA-PEG NPs loaded with docetaxel for IV application. Both types of NP 
      formulations demonstrated in vitro characteristics that were considered suitable 
      for IV administration (with long-circulating sustained-release purposes). NP 
      formulations were IV administered to an animal model, and docetaxel's 
      pharmacokinetic and biodistribution profiles were determined and compared between 
      study groups. PLGA and PEGylated PLGA NPs were able to modify the 
      pharmacokinetics and biodistribution of docetaxel. Accordingly, the mode of 
      changes made to pharmacokinetics and biodistribution of docetaxel is attributed 
      to the size and surface properties of NPs. NPs contributed to increased blood 
      residence time of docetaxel fulfilling their role as long-circulating 
      sustained-release drug delivery systems. Surface modification of NPs contributed 
      to more pronounced docetaxel blood concentration, which confirms the role of PEG 
      in conferring long-circulation properties to NPs.
FAU - Rafiei, Pedram
AU  - Rafiei P
AD  - Division of Pharmacy, College of Pharmacy and Nutrition, University of 
      Saskatchewan, Saskatoon, SK, Canada.
FAU - Haddadi, Azita
AU  - Haddadi A
AD  - Division of Pharmacy, College of Pharmacy and Nutrition, University of 
      Saskatchewan, Saskatoon, SK, Canada.
LA  - eng
PT  - Journal Article
DEP - 20170127
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Taxoids)
RN  - 0 (poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer)
RN  - 15H5577CQD (Docetaxel)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 34346-01-5 (Polyglactin 910)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/blood/*pharmacokinetics
MH  - Chemistry, Pharmaceutical
MH  - Docetaxel
MH  - Drug Carriers/administration & dosage/*chemistry
MH  - *Drug Delivery Systems
MH  - Female
MH  - Humans
MH  - Lactic Acid/*chemistry
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nanoparticles/*chemistry
MH  - Particle Size
MH  - Polyethylene Glycols/*chemistry
MH  - Polyglactin 910/*chemistry
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Taxoids/administration & dosage/blood/*pharmacokinetics
MH  - Tissue Distribution
PMC - PMC5291330
OTO - NOTNLM
OT  - biodistribution
OT  - docetaxel
OT  - emulsification solvent evaporation
OT  - pharmacokinetics
OT  - poly(lactide-co-glycolide)
OT  - poly(lactide-co-glycolide)-poly(ethylene glycol)
OT  - polymeric nanoparticles
OT  - sustained release
COIS- The authors report no conflicts of interest in this work.
EDAT- 2017/02/12 06:00
MHDA- 2017/04/05 06:00
PMCR- 2017/01/27
CRDT- 2017/02/11 06:00
PHST- 2017/02/11 06:00 [entrez]
PHST- 2017/02/12 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
PHST- 2017/01/27 00:00 [pmc-release]
AID - ijn-12-935 [pii]
AID - 10.2147/IJN.S121881 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2017 Jan 27;12:935-947. doi: 10.2147/IJN.S121881. eCollection 
      2017.